Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

Blueprint Medicines (BPMC) shares ended the last trading session 18.2% higher at $103.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Cade Cunningham leading Pistons back to relevancy Detroit is relevant in basketball circles again and Cade Cunningham is a ...

Florida Gov. Ron DeSantis has appointed five new members to the board overseeing the University of West Florida in Pensacola, ...

Gov. Laura Kelly looks back on the roster of bipartisan tax, education, child welfare, worker compensation and other policy accomplishments during 2024. The Democratic governor will outline her 2025 p ...

Series record: Ravens lead 36-15. Last meeting: Browns beat Ravens 29-24 on Oct ... Garrett recently said he wants to see the ...

Gov. Laura Kelly looks back on the roster of bipartisan tax, education, child welfare, worker compensation and other policy ...

The cold February rain fell as dozens of public school advocates bundled together in the dark outside the Maryland State House. Holding umbrellas and flashing blue lights as ...

ETFs One of the easiest ways for Main Street investors to own alts is through a mutual fund or exchange-traded fund (ETF). They trade daily, which solves the liquidity problem, but experts say that ...